📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Trevena

1.1 - Company Overview

Trevena Logo

Trevena

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of an approved intravenous opioid analgesic (OLINVYK) for the management of acute pain in adults when alternative treatments are inadequate, and developer of GPCR-biased ligands, including TRV045 (oral S1P receptor; diabetic neuropathic pain and epilepsy; Phase 1), TRV250 (delta receptor; acute migraine; Phase 1), and TRV734 (oral mu receptor; maintenance treatment of opioid use disorder; Phase 1).

Products and services

  • OLINVYK: An approved intravenous opioid analgesic for the management of acute pain in adults when alternative treatments are inadequate
  • TRV734: A Phase 1 oral candidate targeting the mu receptor for the maintenance treatment of opioid use disorder
  • TRV045: A Phase 1 oral compound targeting the S1P receptor for the treatment of diabetic neuropathic pain and epilepsy

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Trevena

Proximagen Logo

Proximagen

HQ: United Kingdom Website
  • Description: Provider of neuroscience research and drug development targeting neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease; publicly traded.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Proximagen company profile →
Neuraxpharm Logo

Neuraxpharm

HQ: Germany Website
  • Description: Provider of branded and generic CNS pharmaceuticals and nutraceuticals in main European countries, developing and commercializing products for CNS disorder prevention and treatment. Develops and manufactures finished dosage forms (mainly solid oral) for CNS and other areas; includes Buccolam for acute pediatric seizures and Preventan for immune support. Also offers LepsiApp for epilepsy management, R&D (actives, bioequivalence, regulatory), and pharmacovigilance.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Neuraxpharm company profile →
Silo Pharma Logo

Silo Pharma

HQ: United States Website
  • Description: Provider of developmental-stage biopharmaceutical research merging traditional therapeutics with psychedelic research, developing: SPC-15, an intranasal 5-HT(4) receptor agonist for PTSD and stress-induced anxiety; SP-26, a ketamine-based injectable dissolvable implant for chronic pain and fibromyalgia; SPC-14, an intranasal compound for Alzheimer’s targeting NDMARS and 5HT4Rs to treat cognitive and neuropsychiatric symptoms; and SPU-16, a CNS homing peptide for MS and other neuroinflammatory pathologies, improving delivery and reducing toxicity of therapeutics.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Silo Pharma company profile →
Alzheon Logo

Alzheon

HQ: United States Website
  • Description: Provider of clinical-stage treatments for neurodegenerative disorders, including ALZ-801/valiltramiprosate, an oral treatment in Phase 3 testing for Alzheimer’s disease designed to inhibit amyloid oligomer formation; a discovery platform for small molecule inhibitors of protein misfolding; and an expanded access policy for investigational drugs.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Alzheon company profile →
iZumi Bio Logo

iZumi Bio

HQ: United States Website
  • Description: Provider of biotechnology solutions leveraging cellular reprogramming, including induced pluripotent stem cells and directed differentiation, to develop stem cell-based therapeutics.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full iZumi Bio company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Trevena

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Trevena

2.2 - Growth funds investing in similar companies to Trevena

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Trevena

4.2 - Public trading comparable groups for Trevena

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Trevena

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Trevena

What does Trevena do?

Trevena is a provider of an approved intravenous opioid analgesic (OLINVYK) for the management of acute pain in adults when alternative treatments are inadequate, and developer of GPCR-biased ligands, including TRV045 (oral S1P receptor; diabetic neuropathic pain and epilepsy; Phase 1), TRV250 (delta receptor; acute migraine; Phase 1), and TRV734 (oral mu receptor; maintenance treatment of opioid use disorder; Phase 1).

Who are Trevena's competitors?

Trevena's competitors and similar companies include Proximagen, Neuraxpharm, Silo Pharma, Alzheon, and iZumi Bio.

Where is Trevena headquartered?

Trevena is headquartered in United States.

How many employees does Trevena have?

Trevena has 1,000 employees 🔒.

When was Trevena founded?

Trevena was founded in 2010 🔒.

What sector and industry vertical is Trevena in?

Trevena is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Trevena

Who are the top strategic acquirers in Trevena's sector and industry

Top strategic M&A buyers and acquirers in Trevena's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Trevena?

Top strategic M&A buyers groups and sectors for Trevena include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Trevena's sector and industry vertical

Which are the top PE firms investing in Trevena's sector and industry vertical?

Top PE firms investing in Trevena's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Trevena's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Trevena's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Trevena's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Trevena include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Trevena's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Trevena?

The key public trading comparables and valuation benchmarks for Trevena include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Trevena for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Trevena with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Trevena's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Trevena with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Trevena's' sector and industry vertical?

Access recent funding rounds and capital raises in Trevena's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Trevena